ICI治疗胃肠道肿瘤疗效预测标志物的研究进展  

Research progress of ICI prognostic markers in the treatment of gastroint estinal tumors

作　　者：胡杭琦 方明治[2] 李敏[2] HU Hangqi;FANG Mingzhi;LI Min(Nanjing University of Traditional Chinese Medicine,Nanjing Jiangsu 210012;Nanjing Hospital of Traditional Chinese Medicine,Nanjing University of Chinese Medicine,Nanjing Jiangsu 210012)

机构地区：[1]南京中医药大学,江苏南京210012 [2]南京中医药大学附属南京中医院,江苏南京210012

出　　处：《当代医药论丛》2023年第4期36-39,共4页

基　　金：YKK15122(南京市医学科技发展项目);QRX17187(十三五南京市卫生青年人才培养工程)。

摘　　要：肿瘤免疫治疗因其显著的临床获益已成为除手术、化疗、放疗及靶向治疗之外的新型肿瘤治疗方式。免疫检查点抑制剂(immune checkpoint inhibitors,ICI)治疗作为肿瘤免疫治疗的方法之一,目前已被批准用于多种晚期恶性肿瘤的治疗,但仅对部分患者产生良好的免疫应答,这限制了其在临床上的广泛应用。研究ICI疗效预测的相关生物标志物对筛选出合适的目标获益人群至关重要。本文将对ICI治疗胃肠道肿瘤疗效预测标志物的研究进展进行综述,旨在为肿瘤的个体化预防和治疗提供参考依据。Tumor immunotherapy has become a new type of tumor therapy in addition to surgery,chemotherapy,radiotherapy and targeted therapy due to its remarkable clinical benefits.As one of the methods of tumor immunotherapy,immune checkpoint inhibitors(ICI)have been approved for the treatment of a variety of advanced malignant tumors at present,but only good immune response is produced in some patients,which limits its wide application in clinical practice.It is very important to study related biomarkers of ICI efficacy prediction to screen out appropriate target benefit population.This paper will review the research progress of ICI in predicting therapeutic markers for gastrointestinal tumors,aiming to provide reference for individualized prevention and treatment of tumors.

关 键 词：免疫检查点抑制剂 胃肠道肿瘤 PD-1/PD-L1 错配修复功能缺陷/微卫星高度不稳定 肿瘤突变负荷 

分 类 号：R73[医药卫生—肿瘤]